老年体弱人群中羟氯喹风险评估的进展
Progress in the risk assessment of hydroxychloroquine in frail elderly people.
作者信息
Castagna Alberto, Ruotolo Giovanni, Manzo Ciro
机构信息
Azienda Sanitaria Provinciale Catanzaro, Primary Care Departiment, Center for Cognitive Disorders and Dementia Catanzaro Italy.
Geriatric Unit General Hospital Azienda Ospedaliera Pugliese-Ciaccio di Catanzaro Catanzaro Italy.
出版信息
Aging Med (Milton). 2020 Dec 25;4(1):53-57. doi: 10.1002/agm2.12140. eCollection 2021 Mar.
Abstract
Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti-inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID-19 pandemic. However, HCQ can cause QT interval prolongation. The current therapies used in COVID-19 are changing as the pandemic develops. The aim of this article is to promote a validated risk score for QT prolongation in multidimensional assessment of COVID-19 patients, especially in elderly and polypathological patients.
摘要
羟氯喹啉（HCQ）是一种抗疟药物，也具有抗炎和抗病毒作用。由于其作用机制以及在当前新冠疫情期间可能的潜在用途，HCQ的抗病毒作用一直是许多研究人员关注的焦点。然而，HCQ可导致QT间期延长。随着疫情发展，目前用于新冠的治疗方法也在不断变化。本文旨在推广一种经过验证的用于新冠患者多维评估中QT间期延长的风险评分，尤其是针对老年患者和患有多种疾病的患者。
相似文献
1
Progress in the risk assessment of hydroxychloroquine in frail elderly people.老年体弱人群中羟氯喹风险评估的进展
Aging Med (Milton). 2020 Dec 25;4(1):53-57. doi: 10.1002/agm2.12140. eCollection 2021 Mar.
2
QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.COVID-19 患者中羟氯喹和蛋白酶抑制剂相关的 QT 延长。
J Clin Pharm Ther. 2021 Jun;46(3):800-806. doi: 10.1111/jcpt.13356. Epub 2021 Mar 25.
3
Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.羟氯喹/阿奇霉素治疗与 COVID-19 住院患者的 QT 间期延长。
JACC Clin Electrophysiol. 2021 Jan;7(1):16-25. doi: 10.1016/j.jacep.2020.07.016. Epub 2020 Aug 5.
4
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
5
QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia.新冠疫情早期，在使用或未使用阿奇霉素的情况下给予羟氯喹/氯喹治疗期间QT间期和复极离散度的变化：来自印度尼西亚两家学术医院的一项前瞻性观察研究。
J Arrhythm. 2021 Aug 28;37(5):1184-1195. doi: 10.1002/joa3.12623. eCollection 2021 Oct.
6
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.羟氯喹在不同临床环境下 COVID-19 患者中的心律失常安全性。
Europace. 2020 Dec 23;22(12):1855-1863. doi: 10.1093/europace/euaa216.
7
Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.评估 COVID-19 患者的 QT 间期：羟氯喹-阿奇霉素联合方案的安全性。
Int J Cardiol. 2021 Feb 1;324:242-248. doi: 10.1016/j.ijcard.2020.09.038. Epub 2020 Sep 19.
8
Effects of hydroxychloroquine treatment on QT interval.羟氯喹治疗对 QT 间期的影响。
Heart Rhythm. 2020 Nov;17(11):1930-1935. doi: 10.1016/j.hrthm.2020.06.029. Epub 2020 Jun 28.
9
System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.羟氯喹和阿奇霉素靶点的系统生物学研究及其对 QT 间期延长的影响。
Chem Biol Interact. 2020 Dec 1;332:109299. doi: 10.1016/j.cbi.2020.109299. Epub 2020 Oct 22.
10
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.与阿奇霉素联合或不联合氯喹或羟氯喹相关的QT间期延长或尖端扭转型室速的安全信号。
Res Social Adm Pharm. 2021 Feb;17(2):483-486. doi: 10.1016/j.sapharm.2020.04.016. Epub 2020 Apr 19.
本文引用的文献
1
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.评价在 ClinicalTrials.gov 上注册的心血管治疗 COVID-19 的临床试验特征：一项横断面分析。
Am Heart J. 2021 Feb;232:105-115. doi: 10.1016/j.ahj.2020.10.065. Epub 2020 Oct 26.
2
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
3
Comment on: Coronavirus 2019 in Geriatrics and Long-Term Care: The ABCDs of COVID-19.评论：老年病学和长期护理中的 2019 年冠状病毒：COVID-19 的 ABCD。
J Am Geriatr Soc. 2020 Dec;68(12):2746. doi: 10.1111/jgs.16795. Epub 2020 Sep 9.
4
Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤稿——羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册研究分析
Lancet. 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6. Epub 2020 Jun 5.
5
Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.羟氯喹预防新型冠状病毒肺炎——寻找证据
N Engl J Med. 2020 Aug 6;383(6):585-586. doi: 10.1056/NEJMe2020388. Epub 2020 Jun 3.
6
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
7
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。
Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.
8
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.羟氯喹或氯喹治疗或预防 COVID-19：一项实时系统评价。
Ann Intern Med. 2020 Aug 18;173(4):287-296. doi: 10.7326/M20-2496. Epub 2020 May 27.
9
Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?氯喹或羟氯喹用于治疗新型冠状病毒肺炎：为何它们可能具有危险性？
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31174-0.
10
Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.羟氯喹、伊维菌素和阿奇霉素药物在抗击新冠病毒中的潜在用途：趋势、范围及相关性
New Microbes New Infect. 2020 Apr 22;35:100684. doi: 10.1016/j.nmni.2020.100684. eCollection 2020 May.
Zotero 插件